Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab
- Conditions
- TrastuzumabAntitumor DrugsCardiotoxicityBreast Cancer
- Interventions
- Registration Number
- NCT04961307
- Lead Sponsor
- Peking University Third Hospital
- Brief Summary
By dynamically observing the changes of echocardiogram and biomarkers in breast cancer patients using trastuzumab, evaluate the effect of trastuzumab on cardiac function; determine the sensitivity of echocardiography and biomarker indicators And specificity, explore effective and specific early warning indicators, and provide technical support for the evaluation of the cardiac safety of anti-tumor drugs.
- Detailed Description
Thirty female breast cancer patients using trastuzumab, collected demographic and clinical information of all patients before chemotherapy, performed echocardiography (conventional echocardiography, three-dimensional spot tracking technology), and collected blood samples to detect plasma biology Markers (TnT, BNP, GDF-15, topoisomerase), follow-up echocardiography and biomarkers at 1 month, 3 months and 6 months after chemotherapy.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 30
- Patients with breast cancer (18-70 years old)
- Patients who are planning to undergo trastuzumab for the first time
- Organic heart disease such as coronary heart disease, heart valve disease, cardiomyopathy
- liver and kidney failure
- severe cerebrovascular disease
- chronic obstructive pulmonary disease
- rheumatic immune system disease
- other tumors
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Women with breast cancer using trastuzumab Trastuzumab -
- Primary Outcome Measures
Name Time Method Time ending 6 months 180 days after chemotherapy
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Peking University Third Hospital
🇨🇳Peking, Beijing, China